Prognostic Significance of Baseline Positron Emission Tomography and Importance of Clinical Complete Response in Patients With Esophageal or Gastroesophageal Junction Cancer Treated With Definitive Chemoradiotherapy
Prognostic Significance of Baseline Positron Emission Tomography and Importance of Clinical Complete Response in Patients With Esophageal or Gastroesophageal Junction Cancer Treated With Definitive Chemoradiotherapy
复制标题
DOI：
10.1002/cncr.26122
复制
发表时间：
2011-11-01
期刊：
影响因子：
6.2
通讯作者：
Ajani, Jaffer A.
中科院分区：
文献类型：
--
作者：
Suzuki, Akihiro;Xiao, Lianchun;Ajani, Jaffer A.
背景技术背景：代谢成像是感兴趣的食管癌;然而，在食管或胃食管癌患者接受明确的放化疗治疗的正电子发射断层扫描（PET）的初始标准化摄取值（SUV）的有用性是未知的。作者假设初始SUV与患者结局相关。方法：作者回顾性分析了除其他常规分期外还进行了基线PET和内镜超声检查的食管癌或胃食管癌患者。所有患者均接受了明确的放化疗。采用多种统计方法。研究结果：作者分析了209例接受明确放化疗治疗的连续食管癌或胃食管癌患者的结局;其中180例患者接受了基线PET进行额外分析。所有患者的中位总生存期（OS）为20.7个月（95%置信区间，18.8-26.3）。临床完全缓解（CR）患者的生存时间长于临床CR（P <0.0001）。初始SUV中位数为12.7（范围：0-51）。较高的初始SUV与肿瘤较长（P = .0001）、较高的T分期状态（P < .0001）、阳性N分期状态（P = .0001）、较高的总体分期（P < .0001）、临床CR缺乏（P = .0002）和鳞状细胞组织学（P <.0001）相关。
BACKGROUND: Metabolic imaging is of interest in esophageal cancer; however, the usefulness of initial standardized uptake value (SUV) in positron emission tomography (PET) is unknown in patients with esophageal or gastroesophageal carcinoma treated with definitive chemoradiotherapy. The authors hypothesized that initial SUV would correlate with patient outcome. METHODS: The authors retrospectively analyzed esophageal or gastroesophageal carcinoma patients who had baseline PET and endoscopic ultrasonography in addition to other routine staging. All patients received definitive chemoradiotherapy. Multiple statistical methods were used. RESULTS: The authors analyzed 209 consecutive esophageal or gastroesophageal carcinoma patients treated with definitive chemoradiation for outcome; of these, 180 had baseline PET for additional analyses. The median overall survival (OS) for all patients was 20.7 months (95% confidence interval, 18.8-26.3). Patients with clinical complete response (CR) lived longer than those with less than clinical CR (P < .0001). The median initial SUV was 12.7 (range, 0-51). Higher initial SUV was associated with longer tumors (P = .0001), higher T-stage status (P < .0001), positive N-stage status (P = .0001), higher overall stage (P < .0001), lack of clinical CR (P = .0002), and squamous cell histology (P